What happened
HCW Biologics Inc. (NASDAQ: HCWB) ended the third quarter with $955,458 in cash, 51.1% below its Dec. 31, 2025 balance of $1.95 million.
The clinical-stage drugmaker also says substantial doubt exists about its ability to continue as a going concern for at least 12 months without more funding or financial support. It reported the figures on Nov. 16 for the three and nine months ended Sept. 30.
The company added debt after quarter-end. On Nov. 4, it secured up to $10.0 million. It received $3.0 million, less transaction costs, at closing. It can access another $7.0 million if certain conditions are met. The company believes this funds it through the HCW9302 Phase 1 trial and the Recommended Phase 2 Dose determination.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
Where the revenue comes from
Nine-month revenue reached $6.73 million, up from $27,222 a year earlier. The latest quarter added little. Third-quarter revenue was $55,463 against $15,606 a year earlier, so nearly all of the nine-month total arrived in the first six months.
The filing's revenue discussion points to licensing. In the nine months, the company closed an exclusive, worldwide license with Beijing Trimmune Biotech Co., Ltd. for in vivo rights to HCW11-006. It also performed post-transfer services. The company ended its license with AlloTera Therapeutics, Inc. and took back the exclusive rights. A year earlier, with that license suspended, revenue came only from minor ancillary services such as storage.
By OptimistFi's calculation, the nine-month operating loss narrowed 71.0% to $2.5 million. The improvement came from revenue, not lower spending. Operating expenses rose 3.2% to $8.99 million from $8.71 million. The 2025 figure was held down by a $2.0 million insurance recovery that offset legal costs.
Net loss for the nine months was $5.0 million against $8.7 million a year earlier. The 2026 figure includes a $1.8 million nonoperating loss, mainly from a drop in the fair value of a warrant liability that was reclassified to equity. In the third quarter, net loss was $3.2 million against $4.6 million. After a $14.4 million equity dividend to an investor, the nine-month net loss attributable to common stockholders was $19.3 million.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
What the balance sheet shows
Liquidity is thin against obligations. Current assets were $1.28 million at Sept. 30. Current liabilities were $17.6 million, including $6.83 million of short-term debt, net.
Accounts payable fell 28.2% to $9.4 million from $13.1 million at Dec. 31, 2025. Stockholders' equity rose to $6.82 million from $2.76 million. The company raised $8.6 million of equity financing in the nine months.
Cash is the scarce item on the asset side. Investments rose to $4.85 million from $1.33 million. Property, plant and equipment of $18.96 million make up most of the $25.13 million in total assets.
Why it matters
OptimistFi has argued that HCW Biologics is a cash-constrained biotech option. In its view, the value depends on turning HCW9302 immunotherapy IP into fundable clinical progress before liquidity runs out. This filing supports both halves of that view. The trial is moving, and the cash is thin.
On progress, the company activated an additional clinical site for the HCW9302 Phase 1 study in alopecia areata. It also kept enrolling in the third dose cohort, eight micrograms per kilogram of body weight. In patients treated to date, subcutaneous administration has been well tolerated with no dose-limiting toxicities. That is a tolerability result so far, not efficacy data.
On the other side, the new money is built to reach one milestone. The company still flagged going-concern doubt as of Sept. 30. Only the first tranche of the debt has been received, and the rest depends on conditions. The revenue jump came with a license closing, while the latest quarter's own revenue was small.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
What's next
The Phase 1 readout and the Recommended Phase 2 Dose determination are expected in the first quarter of 2027. The company plans to present full results in an invited oral presentation at the 9th Treg-Directed Therapies Summit in March 2027 in Boston. A clean readout with a chosen Phase 2 dose would give HCW Biologics something to take to partners or investors.
A delay, or dose-limiting toxicity in later cohorts, would test the funding the company says it has in place.
A second item is due in the first half of 2027. After a Type B meeting, the U.S. Food and Drug Administration gave the company clear guidance on preparing an IND application for a first-in-human solid tumor study of HCW11-018b. The company plans to file in that window. It has already started cGMP manufacturing of HCW11-018b.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
Guidance is management's forecast, not a completed result.

